Windlas Biotech Reports Record Revenue of Rs 248 Crores in Q1 FY27; Highlights Strong CDMO Vertical Performance

Windlas Biotech Reports Record Revenue of Rs 248 Crores in Q1 FY27; Highlights Strong CDMO Vertical Performance​

Windlas Biotech Limited, a leading player in India's pharmaceutical contract development and manufacturing organization (CDMO) industry, reported its unaudited financial results for the quarter ended June 30, 2026. The company announced record revenue of Rs 248 crores for Q1 FY27, marking continuous growth across operations.

The consolidated highlights showed that Revenue from operations stood at Rs 248 crores, an increase of 18% year-on-year (YoY), compared to Rs 210 crores in the previous period. Adjusted EBITDA reached Rs 34 crores, demonstrating a 26% YoY growth, while the Adjusted PAT grew by 37% YoY to reach Rs 25 crores. The company also reported an Earnings Per Share (EPS) of Rs 8.46.

One of the significant corporate actions was the completion of a Rs 47 crore share buyback, which occurred without promoter participation. Furthermore, Windlas Biotech paid a dividend of Rs 13 crores or Rs 6.3 per share for FY26.

Vertical Performance Breakdown​

The company detailed performance across its three key verticals: Generic Formulations CDMO, Trade Generics & Institutional, and Exports.


The Generic Formulations CDMO vertical, which contributed approximately 84% to the consolidated revenue in Q1FY27, saw its revenue reach Rs 207 crores from Rs 160 crores in Q1FY26. The Exports vertical demonstrated strong growth, with revenue rising 79% YoY to Rs 11 crores. Conversely, the Trade Generics & Institutional vertical recorded a revenue of Rs 30 crores for Q1FY27, down 32% YoY.

Management Commentary on Results​

Commenting on the results, Mr. Hitesh Windlass, Managing Director, noted that the company delivered its highest-ever quarterly revenue at ₹248 crore, reflecting 18% YoY growth amid a measured industry environment. He attributed this performance to the resilience of the diversified business model and operational excellence. Mr. Windlass added that the company is on track for the commercialization of Plant-6 in H1 FY27, which will boost manufacturing capacity.

Ms. Komal Gupta, CEO & CFO, highlighted the continued record streak across 14 consecutive quarters with revenue reaching Rs 248 crore. She stated that excluding non-cash ESOP expenses amounting to ₹7.2 Crore, EBITDA grew 26% YoY to ₹34 crore.

Ms. Gupta provided specific insights into vertical performance. She noted that the Generic Formulations CDMO vertical drove growth through customer expansion and new product launches. In the Trade Generics & Institutional vertical, revenue was reported at Rs 30 crores following the discontinuation of codeine-based products, though management expressed confidence in bridging this gap as they expand their portfolio with new launches and replacements. The Exports vertical recorded a robust 79% YoY growth to Rs 11 crore.

The company emphasized its focus on long-term shareholder value creation, disciplined execution, talent development, and accelerating portfolio development across all business verticals.

WINDLAS Stock Price Movement​

Shares of Windlas Biotech Limited today slipped by 6.99% to settle at ₹839.65 after market close. The stock accounted for a total traded volume of 114,664 shares during the session.